(Total Views: 540)
Posted On: 11/25/2024 10:29:46 AM
Post# of 154922
"Dr. Pestell will lead the Company’s research and development strategy in oncology and utilize his expertise and vast network to further CytoDyn’s clinical evaluation of the capabilities for leronlimab in cancer treatment."
Perhaps it is better to build and rebuild bridges vs reducing our options, considering our low cash and anonymous position (to a large portion of the medical community). I view the "vast network" as equally important to his expertise. Just trying to see the sunshine through the clouds. So far, I have not lost faith in Dr Jay. However, soon, we need to see some positive impact on our, dismal, share price.
Investors Hangout: https://investorshangout.com/post/view?id=673...z8sbfFr7Gr
Perhaps it is better to build and rebuild bridges vs reducing our options, considering our low cash and anonymous position (to a large portion of the medical community). I view the "vast network" as equally important to his expertise. Just trying to see the sunshine through the clouds. So far, I have not lost faith in Dr Jay. However, soon, we need to see some positive impact on our, dismal, share price.
Investors Hangout: https://investorshangout.com/post/view?id=673...z8sbfFr7Gr
(14)
(0)
